Global and United States Newborn Screening for SMA and SCID Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Newborn Screening for SMA and SCID Market Report & Forecast 2024-2034
Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.
Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections.
Spinal muscular atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons—nerve cells in the brain stem and spinal cord that control essential skeletal muscle activity such as speaking, walking, breathing, and swallowing, leading to muscle weakness and atrophy.
Market Analysis and InsightsGlobal and United States Newborn Screening for SMA and SCID Market
This report focuses on global and United States Newborn Screening for SMA and SCID market, also covers the segmentation data of other regions in regional level and county level.
The global Newborn Screening for SMA and SCID revenue was US$ 129.2 million in 2024 and is forecast to a readjusted size of US$ 288 million by 2034 with a CAGR of 11.5% during the review period (2024-2034).
Global key players providing newborn screening for SMA and SCID are Perkinelmer, Thermo Fisher, ImmunoIVD, and Labsystems Diagnostics. The top four companies together hold 90% of the market share, with the largest vendor being Perkinelmer with 60% of the market share. The global companies providing newborn SMA and SCID screening are mainly located in North America and Europe, with North America holding the largest market share with 60%. In terms of product categories, kits dominate the market with 60% market share, followed by instruments and software with 35% and 5% market share, respectively. In terms of applications, SCID screening holds a 65% market share, while SMA screening is 35%.
Global Newborn Screening for SMA and SCID Scope and Market Size
Newborn Screening for SMA and SCID market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Newborn Screening for SMA and SCID market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2034.
For United States market, this report focuses on the Newborn Screening for SMA and SCID market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
Perkinelmer
Thermo Fisher
ImmunoIVD
Labsystems Diagnostics
Segment by Type
Instruments
Kits
Software
SCID Screening
SMA Screening
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Newborn Screening for SMA and SCID definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Newborn Screening for SMA and SCID companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Newborn Screening for SMA and SCID in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Newborn Screening for SMA and SCID revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections.
Spinal muscular atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons—nerve cells in the brain stem and spinal cord that control essential skeletal muscle activity such as speaking, walking, breathing, and swallowing, leading to muscle weakness and atrophy.
Market Analysis and InsightsGlobal and United States Newborn Screening for SMA and SCID Market
This report focuses on global and United States Newborn Screening for SMA and SCID market, also covers the segmentation data of other regions in regional level and county level.
The global Newborn Screening for SMA and SCID revenue was US$ 129.2 million in 2024 and is forecast to a readjusted size of US$ 288 million by 2034 with a CAGR of 11.5% during the review period (2024-2034).
Global key players providing newborn screening for SMA and SCID are Perkinelmer, Thermo Fisher, ImmunoIVD, and Labsystems Diagnostics. The top four companies together hold 90% of the market share, with the largest vendor being Perkinelmer with 60% of the market share. The global companies providing newborn SMA and SCID screening are mainly located in North America and Europe, with North America holding the largest market share with 60%. In terms of product categories, kits dominate the market with 60% market share, followed by instruments and software with 35% and 5% market share, respectively. In terms of applications, SCID screening holds a 65% market share, while SMA screening is 35%.
Global Newborn Screening for SMA and SCID Scope and Market Size
Newborn Screening for SMA and SCID market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Newborn Screening for SMA and SCID market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2034.
For United States market, this report focuses on the Newborn Screening for SMA and SCID market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
By Company
Perkinelmer
Thermo Fisher
ImmunoIVD
Labsystems Diagnostics
Segment by Type
Instruments
Kits
Software
Segment by Application
SCID Screening
SMA Screening
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Newborn Screening for SMA and SCID definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Newborn Screening for SMA and SCID companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Newborn Screening for SMA and SCID in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Newborn Screening for SMA and SCID revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices